Trinity Legacy Partners LLC increased its position in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 3.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 107,348 shares of the biopharmaceutical company’s stock after buying an additional 3,838 shares during the period. Pfizer comprises about 2.2% of Trinity Legacy Partners LLC’s portfolio, making the stock its 15th biggest position. Trinity Legacy Partners LLC’s holdings in Pfizer were worth $5,501,000 at the end of the most recent reporting period.
A number of other large investors have also recently made changes to their positions in PFE. RB Capital Management LLC increased its stake in shares of Pfizer by 6.7% during the first quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock worth $282,000 after buying an additional 341 shares during the period. Ironwood Wealth Management LLC. boosted its holdings in Pfizer by 1.1% in the first quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock valued at $1,868,000 after purchasing an additional 400 shares in the last quarter. United Bank boosted its holdings in Pfizer by 0.6% in the first quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock valued at $2,416,000 after purchasing an additional 290 shares in the last quarter. Ergoteles LLC boosted its holdings in Pfizer by 136.3% in the first quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock valued at $1,903,000 after purchasing an additional 21,209 shares in the last quarter. Finally, Mackenzie Financial Corp boosted its holdings in Pfizer by 6.4% in the first quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock valued at $69,238,000 after purchasing an additional 79,887 shares in the last quarter. 67.62% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of equities analysts recently issued reports on the company. Wells Fargo & Company lowered their price target on Pfizer from $50.00 to $44.00 and set an “equal weight” rating for the company in a report on Friday. Morgan Stanley decreased their price objective on Pfizer from $53.00 to $45.00 and set an “equal weight” rating for the company in a report on Wednesday, February 1st. The Goldman Sachs Group raised Pfizer from a “neutral” rating to a “buy” rating and increased their price objective for the company from $47.00 to $60.00 in a report on Tuesday, December 13th. Cantor Fitzgerald reissued an “overweight” rating and issued a $75.00 price objective on shares of Pfizer in a report on Wednesday, February 1st. Finally, Credit Suisse Group decreased their price target on Pfizer from $54.00 to $50.00 and set an “outperform” rating for the company in a report on Wednesday, February 1st. Nine equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $50.38.
Pfizer Trading Down 0.7 %
Pfizer (NYSE:PFE – Get Rating) last released its quarterly earnings data on Tuesday, January 31st. The biopharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.03 by $0.11. The firm had revenue of $24.30 billion during the quarter, compared to analysts’ expectations of $24.40 billion. Pfizer had a return on equity of 42.03% and a net margin of 31.27%. Pfizer’s revenue was up 1.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.08 earnings per share. As a group, sell-side analysts anticipate that Pfizer Inc. will post 3.33 earnings per share for the current fiscal year.
Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Get Rating).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.